Fig. 2.

Treatment failure during anti-TNFα therapy as estimated by UK clinicians. Estimates of treatment failure are consistently lower for first-line biologic therapy (black boxes) compared with second-line biologic therapy (grey boxes) in (a) UC and (b) CD, on the basis of the experience of UK gastroenterologists. Median line with box of 25th/75th percentiles and upper/lower adjacent values; while reading the figure, please observe that each category on the x-axis is assigned two boxes. ADA, adalimumab; anti-TNFα, anti-tumour necrosis factor-α; CD, Crohn’s disease; IFX, infliximab; PF, primary failure; SF, secondary failure; UC, ulcerative colitis.